Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050648 · ClinicalTrials.gov registry record · Phase 1
To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris
A Phase 1 study of Psoriasis, sponsored by Rockefeller University.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 3
- Study locations
NCT00050648: Completed Phase 1 study of Psoriasis, sponsored by Rockefeller University.
NCT00050648 is a Phase 1 study of Psoriasis that has completed, run by Rockefeller University. The registered enrollment target is 20 participants, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00050648, a Phase 1 study of Psoriasis, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study compares the efficacy and analyzes the cellular effects of anti-TAC (Daclizumab) and Cyclosporine in the treatment of psoriasis vulgaris. This is a three-armed study-Daclizumab alone, Cyclosporine alone, and the combination of both Daclizumab and Cyclosporine.
Conditions Studied
Interventions
- DRUG Cyclosporine
- DRUG Daclizumab
- DRUG cyclosporine and Daclizumab
Study Locations (3)
New York
- Rockefeller University Hospital - New York
- Rockefeller University - New York
- Rockefeller University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 1997-10 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
What the finished NCT00050648 record still lists
NCT00050648 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 3 interventions - of which Cyclosporine is the first listed.
NCT00050648 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00050648 about?
NCT00050648 is a clinical study titled "To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris". This study compares the efficacy and analyzes the cellular effects of anti-TAC (Daclizumab) and Cyclosporine in the treatment of psoriasis vulgaris. This is a three-armed study-Daclizumab alone, Cyclosporine alone, and the combination of both Daclizumab and Cyclosporine.
What is the current status of trial NCT00050648?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 1997-10. Estimated completion is 2008-04.
What conditions does trial NCT00050648 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT00050648?
The interventions under investigation include: Cyclosporine (DRUG), Daclizumab (DRUG), cyclosporine and Daclizumab (DRUG).
Who is sponsoring clinical trial NCT00050648?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00050648 being conducted?
This trial has 3 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00050648's enrollment target sits among peer trials
20 107th of 125 higher than 16 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
RECRUITING · Phase 1
-
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
RECRUITING · Phase 1
-
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
RECRUITING · Phase 1
-
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
COMPLETED · Phase 1
-
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia